BLA

Orca prepares to make market plunge after phase 3 win

Orca-T offers “good efficacy and low toxicity,” CEO Ivan Dimov said, noting that the combination of features represents the "holy grail" in the space.

Gabrielle Masson Mar 17, 2025 7:00am

Omeros stock up after data analysis spurs BLA resubmission plan

Dec 19, 2024 10:54am

Biogen tests FDA with controversial aducanumab filing

Jul 8, 2020 10:55am

Troubled Immunomedics tries again at FDA after rejection

Dec 5, 2019 7:20am